Zymeworks Announces New Multispecific Antibody Collaboration with Merck

On July 8, 2020 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms (Press release, Zymeworks, JUL 8, 2020, View Source [SID1234561753]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the new research and license agreement, Zymeworks will provide Merck a worldwide, royalty-bearing license to research, develop and commercialize up to three new multispecific antibodies toward Merck’s therapeutic targets. In exchange, Zymeworks will receive an undisclosed upfront payment and if each of the three programs yield an approved product, Zymeworks is eligible to receive up to US$411 million in option exercise fees and clinical development and regulatory approval milestone payments and up to US$480 million in commercial milestone payments, as well as tiered royalties on worldwide sales.

Merck will also receive a worldwide, royalty-bearing license to research, develop and commercialize up to three multispecific antibodies in the animal health field in exchange for additional milestone payments and tiered royalties.

"It is an exciting time for the field of bispecific and multispecific therapeutics with candidates like ZW25 demonstrating great promise in clinical trials," said Ali Tehrani, Ph.D., President and CEO of Zymeworks. "We are very proud that oncology leaders like Merck recognize the value of our therapeutic platforms and continue to return for expanded access to our technology. We look forward to continuing our relationship with Merck as they advance additional multispecific candidates towards the clinic."

Zymeworks and Merck began working together in 2011 to develop bispecific antibodies in a collaboration that was expanded in 2014. The new agreement does not impact the original agreement.

"Zymeworks’ technology plays a significant role in our efforts to identify and develop multispecific antibody therapies," said Scott Lesley, Ph.D., Vice President of Discovery Biologics, Merck Research Laboratories. "Merck is pleased to continue our collaboration with the Zymeworks team."

About the Azymetric Platform

The Azymetric platform enables the transformation of monospecific antibodies into bispecific and multispecific antibodies, allowing simultaneous binding to several different disease targets. This unique technology enables the development of multifunctional therapeutics that can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting. These features are designed to enhance efficacy while reducing toxicities and the potential for drug resistance. Azymetric therapeutics have been engineered to retain the desirable drug-like qualities of naturally occurring antibodies, including low immunogenicity, long half-life and high stability. In addition, they are compatible with standard manufacturing processes that deliver high yields and purity, potentially reducing drug development costs and timelines.

About the EFECT Platform

The EFECT platform is a library of antibody Fc modifications engineered to activate or suppress the antibody-mediated immune response. This platform, which is compatible with traditional monoclonal as well as Azymetric bispecific antibodies, further enables the customization and optimization of therapeutic responses for different diseases.

Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020

On July 8, 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020, before the U.S. financial markets open (Press release, Regeneron, JUL 8, 2020, https://www.prnewswire.com/news-releases/regeneron-to-report-second-quarter-2020-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-5-2020-301089994.html [SID1234561769]). The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at View Source A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

On July 8, 2020 Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, reported it has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira), which is being developed for the non-surgical treatment of high-grade cervical dysplasia (HSIL) (Press release, Asieris Pharmaceuticals, JUL 8, 2020, View Source [SID1234561754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Receiving the CTA from NMPA for APL-1702 is a significant milestone for the company as it builds and expands its capabilities in the genitourinary disease area," commented Dr. John Zhuang, Asieris’ Chief Operation Officer and APL-1702’s project leader. "APL-1702 has the potential to be the first non-surgical treatment product for cervical precancerous lesions in the world. Female patients of childbearing age have strong desires for a non-surgical treatment that preserves the cervical function, and APL-1702 holds the potential of fulfilling this significant unmet medical need, thereby bringing substantial relief to these patients."

In addition to China, Asieris has concurrently initiated this global pivotal trial in the United States, Germany, Romania, Hungary, Russia, Ukraine and other European countries. Data from this trial will support the market approval applications in China, the United States, the European Union, and other countries.

About Cervical Dysplasia
High grade cervical squamous intraepithelial lesion (HSIL) is a precancerous condition caused by a persistent HPV infection, a highly prevalent sexually transmitted disease. Each year there are approximately 10 million cases with high grade disease and over 50 thousands new cases of cervical cancer worldwide. In China, approximately 2% of the female population develop HSIL each year.
Currently surgical excisions, primarily LEEP/LLETZ and CKC, are the most common treatment options. However, these surgical treatment methods may cause adverse reactions, including bleeding, infection, and damages to the cervix, which may subsequently lead to adverse effects on the reproductive function (such as premature birth, abortion).

About APL-1702 (Cevira)
Cevira is a photodynamic drug-device combination product. Based on the principle of photodynamic therapy, a photosensitizer is combined with light activation of specific wavelength to produce therapeutic effects. APL-1702 is intended for patients of 18 years and older with high-grade cervical dysplasia (HSIL), including all HPV subtype strains.
Cevira is easily placed on the cervix by a gynecologist and removed by the patient at the end of treatment, with no disruption to her normal daily activities during treatment. Only one or two treatments are needed. This breakthrough treatment would provide a new option to both Chinese and overseas patients, allowing them to avoid the pain and adverse reactions associated with surgical procedure, especially avoid the impact of surgery on reproduction.
APL-1702 has received the Fierce Innovation Awards – Life Sciences Edition 2019 in the category of Medical Device Innovation. No non-surgical treatment product has been approved for treating HSIL disease in any country to date.

First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions

On July 8, 2020 On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, reported that it has announced that it has enrolled the first patient in the ELUCIDATE Trial, a Phase 3 clinical trial evaluating the efficacy and safety of pafolacianine sodium (formerly OTL38) in the intraoperative detection of lung cancer lesions (Press release, On Target Laboratories, JUL 8, 2020, View Source [SID1234561770]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This pivotal study is pioneering the use of fluorescence guidance to intraoperatively identify lung cancer in real-time," said Sunil Singhal, M.D., Vice Chair, Translational Research and the William Maul Measey Associate Professor in Surgical Research in the Perelman School of Medicine at the University of Pennsylvania and a member of Penn’s Abramson Cancer Center and principal investigator of the study. "Using a fluorescent imaging marker with high affinity and specificity for lung cancer allows surgeons to more effectively remove all the malignant tissue and have greater confidence in a complete resection."

The Phase 3 study will assess the efficacy, safety, and tolerability of pafolacianine sodium in patients with lung cancer. This multi-center trial is expected to enroll up to 130 patients. Top-line data from the trial are expected in 2021.

"Treating our first patient in the ELUCIDATE Phase 3 Trial is an enormous achievement for On Target Laboratories," said Chris Barys, CEO of On Target Laboratories. "We believe this transformational technology should become the standard of care and look forward to bringing it to market so more lung cancer patients can benefit from the improved outcomes associated with more complete tumor resections."

About Fluorescence-guided Surgery

To date, there have been limited ways for surgeons to confidently assess the location and full extent of cancerous tissue while operating. On Target Laboratories’ fluorescent markers are comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. These markers illuminate the cancerous lesions, lighting the way for the resection of malignant tissue and enabling surgeons to see and remove more diseased tissue.

On Target’s first novel compound, pafolacianine sodium, targets folate receptors commonly found on many cancers, including lung and ovarian cancers. A small single dose of the compound is administered via intravenous infusion prior to surgery, allowing the surgeon to identify malignant tissue during the procedure using a near-infrared camera.

AMN Healthcare to Host Second Quarter 2020 Earnings Conference Call on Thursday, August 6, 2020

On July 8, 2020 AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, reported that has scheduled a conference call to discuss its second quarter 2020 financial results on Thursday, August 6, 2020 at 5:00 p.m. Eastern Time (Press release, AMN Healthcare Services, JUL 8, 2020, View Source [SID1234561771]). The same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the call can be accessed through AMN Healthcare’s website at View Source Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Interested parties may participate live via telephone by dialing (833) 968-2219 in the U.S., or +1 778-560-2894 for international callers, and using participant code 5756627. Following the conclusion of the call, a replay of the webcast will be available at the Company’s website. Alternatively, a telephonic replay of the call will be available beginning at 8 p.m. Eastern Time on August 6, 2020, and can be accessed until 11:59 p.m. Eastern Time on August 20, 2020 by calling (800) 585-8367 in the U.S. or +1 416-621-4642 internationally, with access code 5756627.